Jonathan W. Byrnes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jonathan W. Byrnes has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
Michiaki Imamura
Division of Cardiovascular Surgery, Department of Pediatrics, College of Medicine, University of Arkansas Medical Sciences, Arkansas Children Hospital, Little Rock, Arkansas
8 shared publicationsParthak Prodhan
Department of Pediatrics University of Arkansas Medical Sciences Arkansas Children Hospital Little Rock AR USA
8 shared publications- Adnan T. Bhutta
University of Arkansas Medical Center
6 shared publications Umesh Dyamenahalli
Division of Pediatric Cardiology, Department of Pediatrics, College of Medicine, University of Arkansas Medical Sciences, Arkansas Children Hospital, Little Rock, Arkansas; Division of Pediatric Cardiology, Department of Pediatrics, University of Chicago, Chicago, Illinois
5 shared publicationsRichard Fiser
Division of Pediatric Critical Care, Department of Pediatrics, University of Arkansas for Medical Sciences College of Medicine, Little Rock, AR
3 shared publicationsXiomara Garcia
Division of Pediatric Critical Care, Department of Pediatrics, College of Medicine, University of Arkansas Medical Sciences, Arkansas Children Hospital, Little Rock, Arkansas; Division of Pediatric Cardiology, Department of Pediatrics, College of Medicine, University of Arkansas Medical Sciences, Arkansas Children Hospital, Little Rock, Arkansas
3 shared publications
Latest Publications
- 18 January 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (4) , 530-540
The ACTION VAD registry: A collective five-year experience
- 18 January 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (4) , 530-540
The ACTION VAD registry: A collective five-year experience
- Open Access
- 4 November 2020
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 67 (7) , e124-e126
Biventricular Support Using ProtekDuo Cannula in a Child
We report a successful pediatric bridge to transplant following application of the ProTekDuo Cannula to provide right ventricular support in a 12-year-old child with biventricular cardiomyopathy and on left ventricular assist device support. We are unaware of any other reports of pediatric use of this device in the medical literature.
- 4 November 2020
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 67 (7) , e124-e126
Open AccessBiventricular Support Using ProtekDuo Cannula in a Child
We report a successful pediatric bridge to transplant following application of the ProTekDuo Cannula to provide right ventricular support in a 12-year-old child with biventricular cardiomyopathy and on left ventricular assist device support. We are unaware of any other reports of pediatric use of this device in the medical literature.
- 11 September 2017
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 28 (2) , 214-221
Efficacy and safety of recombinant tissue plasminogen activator for venous thrombosis after paediatric heart surgery
Objective: Reports in the literature of treatment with recombinant tissue plasminogen activator following cardiac surgery are limited. We reviewed our experience to provide a case series of the therapeutic use of tissue plasminogen activator for the treatment of venous thrombosis in children after cardiac surgery. The data describe the morbidity, mortality, and clinical outcomes of tissue plasminogen activator administration for treatment of venous thrombosis in children following cardiac surgery.Design: The study was designed as a retrospective case series.Setting: The study was carried out in a 25-bed cardiac intensive care unit in an academic, free-standing paediatric hospital.Patients: All children who received tissue plasminogen activator for venous thrombosis within 60 days of cardiac surgery, a total of 13 patients, were included.Interventions: Data was collected, collated, and analysed as a part of the interventions of this study.Measurements and main results: Patients treated with tissue plasminogen activator were principally young infants (median 0.2, IQR 0.07–0.58 years) who had recently (22, IQR 12.5–27.3 days) undergone cardiac surgery. Hospital mortality was high in this patient group (38%), but there was no mortality attributable to tissue plasminogen activator administration, occurring within <72 hours. There was one major haemorrhagic complication that may be attributable to tissue plasminogen activator. Complete or partial resolution of venous thrombosis was confirmed using imaging in 10 of 13 patients (77%), and tissue plasminogen activator administration was associated with resolution of chylous drainage, with no drainage through chest tubes, at 10 days after tissue plasminogen activator treatment in seven of nine patients who had upper-compartment venous thrombosis-associated chylothorax.Conclusions: On the basis of our experience with administration of tissue plasminogen activator in children after cardiac surgery, tissue plasminogen activator is both safe and effective for resolution of venous thrombosis in this high-risk population.
- 11 September 2017
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 28 (2) , 214-221
Efficacy and safety of recombinant tissue plasminogen activator for venous thrombosis after paediatric heart surgery
Objective: Reports in the literature of treatment with recombinant tissue plasminogen activator following cardiac surgery are limited. We reviewed our experience to provide a case series of the therapeutic use of tissue plasminogen activator for the treatment of venous thrombosis in children after cardiac surgery. The data describe the morbidity, mortality, and clinical outcomes of tissue plasminogen activator administration for treatment of venous thrombosis in children following cardiac surgery.Design: The study was designed as a retrospective case series.Setting: The study was carried out in a 25-bed cardiac intensive care unit in an academic, free-standing paediatric hospital.Patients: All children who received tissue plasminogen activator for venous thrombosis within 60 days of cardiac surgery, a total of 13 patients, were included.Interventions: Data was collected, collated, and analysed as a part of the interventions of this study.Measurements and main results: Patients treated with tissue plasminogen activator were principally young infants (median 0.2, IQR 0.07–0.58 years) who had recently (22, IQR 12.5–27.3 days) undergone cardiac surgery. Hospital mortality was high in this patient group (38%), but there was no mortality attributable to tissue plasminogen activator administration, occurring within <72 hours. There was one major haemorrhagic complication that may be attributable to tissue plasminogen activator. Complete or partial resolution of venous thrombosis was confirmed using imaging in 10 of 13 patients (77%), and tissue plasminogen activator administration was associated with resolution of chylous drainage, with no drainage through chest tubes, at 10 days after tissue plasminogen activator treatment in seven of nine patients who had upper-compartment venous thrombosis-associated chylothorax.Conclusions: On the basis of our experience with administration of tissue plasminogen activator in children after cardiac surgery, tissue plasminogen activator is both safe and effective for resolution of venous thrombosis in this high-risk population.
Life-threatening airway bleeding after palliation of single ventricle congenital heart disease
Objective To describe acute and mid-term outcomes following presentation with, and treatment for, life-threatening airway bleeding (hemoptysis) in palliated single ventricle congenital heart disease (SV-CHD). Methods Case series of patients with SV-CHD who presented to a large congenital heart centre with hemoptysis between 2004 and 2015. Results Twenty-one episodes of hemoptysis occurred in 12 patients (58% female, median 10.5 (IQR 7.2, 16.4) years). First hemoptysis episode occurred after Fontan completion (n=8), after superior cavopulmonary anastomosis (SCPA, n=3) and in one shunt-dependent patient. Bronchoscopy was performed in conjunction with catheterisation in 14/21 (67%) initial catheterisations. A specific anatomic source of airway bleeding was identified in 95% of bronchoscopy cases and was uniformly distributed in all lobar segments. Transcatheter intervention with systemic-to-pulmonary collateral artery (SPC) occlusion was performed in 28/30 catheterisations. Apart from increased airway bleeding during interventional bronchoscopy (37%), there were no procedural complications. Median hospital length of stay was 9.0 (3.5, 14.5) days with patients undergoing 1.0 (1.0,2.0) catheterisations per episode of hemoptysis. Two SCPA patients did not survive to discharge. During a median follow-up of 32.5 (12.5, 87.5) months, freedom from mortality was 75%, with all three deaths occurring in the SCPA group by 4 months posthemoptysis. Recurrent hemoptysis occurred in 60% of patients. Conclusions Despite the potentially life-threatening nature of hemoptysis in patients with SV-CHD, a policy of bronchoscopic evaluation and transcatheter treatment is safe and may contribute to low mortality at mid-term follow-up in Fontan patients. Hemoptysis in SCPA patients may portend a poor prognosis. Recurrent hemoptysis is common.
Life-threatening airway bleeding after palliation of single ventricle congenital heart disease
Objective To describe acute and mid-term outcomes following presentation with, and treatment for, life-threatening airway bleeding (hemoptysis) in palliated single ventricle congenital heart disease (SV-CHD). Methods Case series of patients with SV-CHD who presented to a large congenital heart centre with hemoptysis between 2004 and 2015. Results Twenty-one episodes of hemoptysis occurred in 12 patients (58% female, median 10.5 (IQR 7.2, 16.4) years). First hemoptysis episode occurred after Fontan completion (n=8), after superior cavopulmonary anastomosis (SCPA, n=3) and in one shunt-dependent patient. Bronchoscopy was performed in conjunction with catheterisation in 14/21 (67%) initial catheterisations. A specific anatomic source of airway bleeding was identified in 95% of bronchoscopy cases and was uniformly distributed in all lobar segments. Transcatheter intervention with systemic-to-pulmonary collateral artery (SPC) occlusion was performed in 28/30 catheterisations. Apart from increased airway bleeding during interventional bronchoscopy (37%), there were no procedural complications. Median hospital length of stay was 9.0 (3.5, 14.5) days with patients undergoing 1.0 (1.0,2.0) catheterisations per episode of hemoptysis. Two SCPA patients did not survive to discharge. During a median follow-up of 32.5 (12.5, 87.5) months, freedom from mortality was 75%, with all three deaths occurring in the SCPA group by 4 months posthemoptysis. Recurrent hemoptysis occurred in 60% of patients. Conclusions Despite the potentially life-threatening nature of hemoptysis in patients with SV-CHD, a policy of bronchoscopic evaluation and transcatheter treatment is safe and may contribute to low mortality at mid-term follow-up in Fontan patients. Hemoptysis in SCPA patients may portend a poor prognosis. Recurrent hemoptysis is common.
- Open Access
- 8 July 2017
- Published by BMJ in BMJ Quality & Safety
- Vol. 27 (1) , 66-72
Utilizing a transfer of care bundle to reduce unplanned readmissions to the cardiac intensive care unit
Hospital-based intensive care is known to be a significant driver of healthcare costs. In the USA, intensive care unit (ICU) care accounted for 13% of all hospital costs in 2005.1 One aspect of ICU care that has been found to be both a driver of cost and a measure of quality is ICU readmissions.1 As a result, readmission to the ICU within a single hospitalisation is now viewed by payers as a potential preventable complication, and payers are beginning to propose denial of charges associated with these episodes of care given the impact on length of stay (LOS) and hospital charges.2 Examples from the literature include data from an adult medicine multicentre database enquiry that demonstrated that patients who were readmitted to an ICU have a 2.5-fold increase in hospital LOS compared with patients who were not readmitted.3 Furthermore, Magruder et al 4 demonstrated a 128% increase in hospital charges associated with an ICU readmission, and this trend was present despite risk adjustment for patient severity of illness.4
- 8 July 2017
- Published by BMJ in BMJ Quality & Safety
- Vol. 27 (1) , 66-72
Open AccessUtilizing a transfer of care bundle to reduce unplanned readmissions to the cardiac intensive care unit
Hospital-based intensive care is known to be a significant driver of healthcare costs. In the USA, intensive care unit (ICU) care accounted for 13% of all hospital costs in 2005.1 One aspect of ICU care that has been found to be both a driver of cost and a measure of quality is ICU readmissions.1 As a result, readmission to the ICU within a single hospitalisation is now viewed by payers as a potential preventable complication, and payers are beginning to propose denial of charges associated with these episodes of care given the impact on length of stay (LOS) and hospital charges.2 Examples from the literature include data from an adult medicine multicentre database enquiry that demonstrated that patients who were readmitted to an ICU have a 2.5-fold increase in hospital LOS compared with patients who were not readmitted.3 Furthermore, Magruder et al 4 demonstrated a 128% increase in hospital charges associated with an ICU readmission, and this trend was present despite risk adjustment for patient severity of illness.4
- 1 August 2016
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 17, S160-S170
Ventricular Assist Devices in Pediatric Cardiac Intensive Care
The objectives of this review are to discuss the process of patient and mechanical device selection, operative management, and postoperative care with a focus on the management of right ventricular failure, anticoagulation strategies, device-related infections and neurologic sequelae. MEDLINE, PubMed. The number of patients with advanced heart failure due to either acquired or congenital heart disease continues to increase, necessitating in some mechanical circulatory support and in others cardiac transplantation. With a limited cardiac donor pool, mechanical circulatory support is playing a greater role in the management of this population. The perioperative morbidity associated with mechanical circulatory support has lessened with improved postoperative management strategies.
- 1 August 2016
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 17, S160-S170
Ventricular Assist Devices in Pediatric Cardiac Intensive Care
The objectives of this review are to discuss the process of patient and mechanical device selection, operative management, and postoperative care with a focus on the management of right ventricular failure, anticoagulation strategies, device-related infections and neurologic sequelae. MEDLINE, PubMed. The number of patients with advanced heart failure due to either acquired or congenital heart disease continues to increase, necessitating in some mechanical circulatory support and in others cardiac transplantation. With a limited cardiac donor pool, mechanical circulatory support is playing a greater role in the management of this population. The perioperative morbidity associated with mechanical circulatory support has lessened with improved postoperative management strategies.
- 8 March 2016
- Published by SAGE Publications in World Journal for Pediatric and Congenital Heart Surgery
- Vol. 7 (2) , 199-209
Noncardiac Challenges in the Cardiac ICU
Outcomes following cardiac intensive care unit (CICU) admission are influenced by many factors including initial cardiac diagnosis, surgical complexity, and burden of critical illness. Additionally, the presence of noncardiac issues may have a significant impact on outcomes and the patient experience during and following an intensive care unit stay. This review focuses on three common noncardiac areas which impact outcomes and patient experience in and beyond the CICU: feeding and growth, pain and analgesia, and anticoagulation. Growth failure and feeding dysfunction are commonly encountered in infants requiring cardiac surgery and have been associated with worse surgical and developmental outcomes. Recent studies most notably in the single ventricle population have demonstrated improved weight gain and outcomes when feeding protocols are implemented. Children undergoing cardiac surgery may experience both acute and chronic pain. Emerging research is investigating the impact of sedatives and analgesics on neurodevelopmental outcomes and quality of life. Improved pain scores and standardized management of pain and withdrawal may improve the patient experience and outcomes. Effective anticoagulation is a critical component of perioperative care but may be complicated by inflammation, multiorgan dysfunction, and patient factors. Advances in monitoring of anticoagulation and emerging therapies are reviewed.
- 8 March 2016
- Published by SAGE Publications in World Journal for Pediatric and Congenital Heart Surgery
- Vol. 7 (2) , 199-209
Noncardiac Challenges in the Cardiac ICU
Outcomes following cardiac intensive care unit (CICU) admission are influenced by many factors including initial cardiac diagnosis, surgical complexity, and burden of critical illness. Additionally, the presence of noncardiac issues may have a significant impact on outcomes and the patient experience during and following an intensive care unit stay. This review focuses on three common noncardiac areas which impact outcomes and patient experience in and beyond the CICU: feeding and growth, pain and analgesia, and anticoagulation. Growth failure and feeding dysfunction are commonly encountered in infants requiring cardiac surgery and have been associated with worse surgical and developmental outcomes. Recent studies most notably in the single ventricle population have demonstrated improved weight gain and outcomes when feeding protocols are implemented. Children undergoing cardiac surgery may experience both acute and chronic pain. Emerging research is investigating the impact of sedatives and analgesics on neurodevelopmental outcomes and quality of life. Improved pain scores and standardized management of pain and withdrawal may improve the patient experience and outcomes. Effective anticoagulation is a critical component of perioperative care but may be complicated by inflammation, multiorgan dysfunction, and patient factors. Advances in monitoring of anticoagulation and emerging therapies are reviewed.
- 1 March 2016
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 17 (3_suppl) , S77-S88
Pediatric Cardiac Intensive Care Society 2014 Consensus Statement
Thrombotic complications are increasingly being recognized as a significant cause of morbidity and mortality in pediatric and congenital heart disease. The objective of this article is to review the medications currently available to prevent and treat such complications. Online searches were conducted using PubMed. Studies were selected for inclusion based on their scientific merit and applicability to the pediatric cardiac population. Pertinent information from each selected study or scientific review was extracted for inclusion. Four classes of medications were identified as potentially beneficial in this patient group: anticoagulants, antiplatelet agents, thrombolytic agents, and novel oral anticoagulants. Data on each class of medication were synthesized into the follow sections: mechanism of action, pharmacokinetics, dosing, monitoring, reversal, considerations for use, and evidence to support. Anticoagulants, antiplatelet agents, and thrombolytic agents are routinely used successfully in the pediatric patient with heart disease for the prevention and treatment of a wide range of thrombotic complications. Although the novel oral anticoagulants have been approved for a limited number of indications in adults, studies on the safety and efficacy of these agents in children are pending.
- 1 March 2016
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 17 (3_suppl) , S77-S88
Pediatric Cardiac Intensive Care Society 2014 Consensus Statement
Thrombotic complications are increasingly being recognized as a significant cause of morbidity and mortality in pediatric and congenital heart disease. The objective of this article is to review the medications currently available to prevent and treat such complications. Online searches were conducted using PubMed. Studies were selected for inclusion based on their scientific merit and applicability to the pediatric cardiac population. Pertinent information from each selected study or scientific review was extracted for inclusion. Four classes of medications were identified as potentially beneficial in this patient group: anticoagulants, antiplatelet agents, thrombolytic agents, and novel oral anticoagulants. Data on each class of medication were synthesized into the follow sections: mechanism of action, pharmacokinetics, dosing, monitoring, reversal, considerations for use, and evidence to support. Anticoagulants, antiplatelet agents, and thrombolytic agents are routinely used successfully in the pediatric patient with heart disease for the prevention and treatment of a wide range of thrombotic complications. Although the novel oral anticoagulants have been approved for a limited number of indications in adults, studies on the safety and efficacy of these agents in children are pending.
- 1 May 2015
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 99 (5) , 1713-1718
Risk Factors for Prolonged Mechanical Ventilation for Children on Ventricular Assist Device Support
- 1 May 2015
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 99 (5) , 1713-1718
Risk Factors for Prolonged Mechanical Ventilation for Children on Ventricular Assist Device Support